A First In-Human Study of Novel PI3K Inhibitor IPI-549 in Patients With Advanced Solid Tumors
May 24th 2017Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses a phase 1/1b first in-human study of IPI-549, a PI3K gamma inhibitor as monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors.
Watch
Copanlisib as a Treatment for Patients With Relapsed/Refractory Indolent B-Cell Lymphoma
May 24th 2017Martin Dreyling, MD, professor of medicine, University of Munich Hospital in Grosshadern, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma.
Watch
Five-Year Follow-Up Results for Nivolumab in NSCLC
May 23rd 2017Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses 5-year follow-up data from the CA209-003 study of nivolumab (Opdivo) in previously treated advanced non-small cell lung cancer (NSCLC).
Watch
Exploring Active Surveillance in Younger Patients With Prostate Cancer
May 23rd 2017Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses a study focused on active surveillance in men with prostate cancer under the age of 60.
Watch
Results for Pembrolizumab as a First-Line Therapy for Advanced Urothelial Carcinoma
May 22nd 2017Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discussed results of the KEYNOTE-052 study of pembrolizumab as a first-line therapy for patients with cisplatin-ineligible advanced urothelial cancer.
Watch